Control group:Best supportive care

4 trials

Sponsors

Tianjin Third Central Hospital, Jinling Hospital, Medical School of Nanjing University, Peking Union Medical College Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog

Conditions

Cancer cachexiaCholangiocarcinomaPrimary liver cancer with malignant peritoneal effusionlung cancer

Phase 2

Efficacy and Safety of Intraperitoneal PD-1 Monoclonal Antibody Therapy for Hepatobiliary Cancers Patients with Malignant Ascites

RecruitingChiCTR2500099190

Jinling Hospital, Medical School of Nanjing UniversityPrimary liver cancer with malignant peritoneal effusion

Start: 2023-08-16Updated: 2025-03-24

Efficacy and safety of tocilizumab in the treatment of malignant solid tumor-associated cachexia: a prospective, open-label, randomized controlled phase II clinical study

Active, not recruitingChiCTR2500109674

Peking Union Medical College HospitalCancer cachexia

Start: 2025-10-01Updated: 2025-09-29

Unknown Phase

A prospective, multicenter study: assessment of efficacy and safety of SBRT combined withindividualized specific activated T cells immunotherapy (TAA-sT/IMPACT) in advanced stage none-small cell lung cancer

Active, not recruitingChiCTR-IIR-16008823

Union Hospital, Tongji Medical College, Huazhong University of Science and Technologlung cancer

Start: 2016-09-01Updated: 2017-04-18

The efficacy and safety of toripalimab combined with lenvatinib as first-line treatment for advanced perihilar cholangiocarcinoma: a non-randomized controlled clinical trial

Active, not recruitingChiCTR2500096816

Tianjin Third Central HospitalCholangiocarcinoma

Start: 2025-02-24Updated: 2025-02-10